Actively Recruiting

Age: 1Year +
All Genders
Healthy Volunteers
ID01821456

Cologne Cohort of Neutropenic Patients (CoCoNut) Non-interventional Cohort Study Assessing Risk Factors, Interventions, and Outcomes in Immunosuppressed Patients With or Without Opportunistic Infections

Led by University Hospital of Cologne · Updated on 2013-04-01

100000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional observational study focused on examining risk factors, treatments, and outcomes in patients who have weakened immune systems due to neutropenia after chemotherapy for various cancers. The study collects detailed data to better understand these patients' health and infection risks. Participants in this study include immunosuppressed patients who have developed neutropenia following chemotherapy. The study observes the use and effectiveness of antiinfective drug therapies among these high-risk patients, aiming to analyze how these treatments work in real-world settings without altering their usual medical care. During the study, researchers collect comprehensive patient data over time to evaluate long-term survival outcomes, particularly looking at hematology and oncology patients two years after their last follow-up. The study involves ongoing monitoring of patient health, interventions, and any opportunistic infections, with participation lasting as long as patients continue to be followed in the cohort.

CONDITIONS

Brief Title

Cologne Cohort of Neutropenic Patients (CoCoNut)

Who Can Participate

Age: 1Year +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is immunosuppressed
  • Patient has developed neutropenia after chemotherapy for any malignant disease
  • Patient is at least 1 year old
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 2 years following last follow-up

Participants who undergo routine care for neutropenia after chemotherapy are observed to collect data on risk factors, interventions, and outcomes.

Periodic visits as per routine clinical care

Trial Site Locations

Total: 1 location

1

University Hospital of Cologne

Cologne, North Rhine-Westphalia, Germany, 50924

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Prospective Clinical Study of 18F-Pentixafor PET Imaging in ...

Hematological Malignancies

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.

J J Vehreschild, M J G T Rüping, H Wisplinghoff...

https://pubmed.ncbi.nlm.nih.gov/20410061

Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.

Maria J G T Vehreschild, Michael von Bergwelt-Baildon, Liliane Tran...

https://pubmed.ncbi.nlm.nih.gov/24798021

Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis.

Maria J G T Vehreschild, David Weitershagen, Lena M Biehl...

https://pubmed.ncbi.nlm.nih.gov/24607558